Literature DB >> 1692986

Immunohistochemical demonstration of tenascin in the normal human limbus with special reference to trabeculectomy.

T Tervo1, G B van Setten, I Lehto, K Tervo, A Tarkkanen, I Virtanen.   

Abstract

Sections from the anterior segment of the fetal and adult human eye and from limbal tissue excised during standard trabeculectomies were studied immunohistochemically with monoclonal antibodies against human tenascin or monoclonal antibodies against cellular fibronectin (cFN). In the fetal eye, tenascin-like immunoreactivity (TEN-LI) was observed in the area of the developing limbus. In the adult eye TEN-LI was most intense at the corneoscleral margin in the stromal tissue and decreased towards the posterior sclera. No reaction was observed in the corneal stroma, but the epithelium showed moderate immunofluorescence. All tissues obtained during trabeculectomy showed similarly strong TEN-LI. The sections from trabecular specimens incubated with antibodies against cFN were negative.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1692986     DOI: 10.1159/000267012

Source DB:  PubMed          Journal:  Ophthalmic Res        ISSN: 0030-3747            Impact factor:   2.892


  4 in total

1.  Tenascin-C expression in normal, inflamed, and scarred human corneas.

Authors:  H Maseruka; R E Bonshek; A B Tullo
Journal:  Br J Ophthalmol       Date:  1997-08       Impact factor: 4.638

2.  Immunohistochemical localization of chondroitin sulfate proteoglycan and tenascin in the human eye compared with the HNK-1 epitope.

Authors:  M Uusitalo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1994-11       Impact factor: 3.117

3.  The expression of tenascin and fibronectin in keratoconus, scarred and normal human cornea.

Authors:  A Tuori; I Virtanen; E Aine; H Uusitalo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-04       Impact factor: 3.117

4.  Increased release of tenascin in tear fluid after photorefractive keratectomy.

Authors:  M Vesaluoma; S Ylätupa; P Mertaniemi; K Tervo; P Partanen; T Tervo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-08       Impact factor: 3.117

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.